151-165 of 301
Building a Multidisciplinary Care Team for Sickle Cell Disease Patients
Project Oncology®Building a Multidisciplinary Care Team for Sickle Cell Disease Patients
Nidhi Bhatt
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Project Oncology®DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Identifying CIDP: A Guide to Risk Profiles and Clinical Presentation
On the Frontlines of CIDPIdentifying CIDP: A Guide to Risk Profiles and Clinical Presentation
Nicolas Dubuisson, MD
Ryan Quigley
Consensus and Standards to Improve Continuity of Care in Sickle Cell Disease
Clinician's RoundtableConsensus and Standards to Improve Continuity of Care in Sickle Cell Disease
Targeting Inflammation to Improve Gene Therapy Outcomes in Sickle Cell Disease
Clinician's RoundtableTargeting Inflammation to Improve Gene Therapy Outcomes in Sickle Cell Disease
Identifying C3G: Key Diagnostic Considerations and Challenges
On the Frontlines of C3GIdentifying C3G: Key Diagnostic Considerations and Challenges
Anuja Java, MD
- advertisement
Transforming C3G Care: New Advances in Targeted Treatment
On the Frontlines of C3GTransforming C3G Care: New Advances in Targeted Treatment
Anuja Java, MD
Gene Therapy Safety in DMD: How to Identify Common Immune Reactions
NeuroFrontiersGene Therapy Safety in DMD: How to Identify Common Immune Reactions
Kaitlin Batley, MD
Optimizing DMD Care Through Multidisciplinary Collaboration
NeuroFrontiersOptimizing DMD Care Through Multidisciplinary Collaboration
Kaitlin Batley, MD
Symptom Control in gMG: Comparing Ravulizumab and Efgartigimod
NeuroFrontiersSymptom Control in gMG: Comparing Ravulizumab and Efgartigimod
Christopher A. Scheiner, MD, PhD
Empowering Patients with CIDP: Education, Support, and Personalized Care Strategies
On the Frontlines of CIDPEmpowering Patients with CIDP: Education, Support, and Personalized Care Strategies
Danielle Minetti
Ryan Quigley
New Frontiers in CIDP Care: Exploring Approved and Emerging Therapies
On the Frontlines of CIDPNew Frontiers in CIDP Care: Exploring Approved and Emerging Therapies
Chafic Karam, MD
Ryan Quigley
- advertisement
Updates from MINT: Inebilizumab Reduces Relapses and Rescue Therapy Use
NeuroFrontiersUpdates from MINT: Inebilizumab Reduces Relapses and Rescue Therapy Use
Richard Nowak, MD, MS
How Diagnostic Delays in gMG Impact Disease Severity, Outcomes, and Quality of Life
NeuroFrontiersHow Diagnostic Delays in gMG Impact Disease Severity, Outcomes, and Quality of Life
John A. Morren, MD, FAAN, FAANEM
Anti-Fibrotic ADCs Show Promise in Muscle Preservation for DMD
NeuroFrontiersAnti-Fibrotic ADCs Show Promise in Muscle Preservation for DMD
